stockrow
Friday 6 November 2026
Export MMED’s income statement to Excel — free account
MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
18.23
1.06
−5.50%
Follow MMED
Alert me
| Apr '26 | Apr '25 | Apr '24 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.53 | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.28 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.09) | — | — |
P/Operating CF |
(115.55) | (173.13) | (173.13) |
P/B ratio |
0.86 | 1.35 | 1.35 |
Price to Tangible BV |
2.50 | 4.27 | 4.27 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(100.78) | (166.59) | (166.59) |
EV/FCF |
(6.40) | (10.58) | (10.58) |
Quick Ratio |
0.71 | 0.82 | — |
Current Ratio |
1.92 | 1.32 | — |
Net Debt/EBITDA |
8.76 | 5.50 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.70 | 1.29 | 0.00 |
Operating CF/Net income |
0.59 | (0.66) | (0.37) |
Capex/Depreciation |
(1.43) | (1.35) | (1.15) |
| (9.59%) | 0.00% | 0.00% | |
| (7.54%) | (10.14%) | 0.00% | |
ROIC |
(3.58%) | (2.73%) | 0.00% |
Return on Tangible Assets |
(24.54%) | (22.78%) | 0.00% |
Average Days of Receivables |
23.53 | 76.63 | 0.00 |
Research and Development Expense of Revenue |
14.44% | 16.06% | 17.70% |
Selling, General and Administrative Expense of Revenue |
38.14% | 39.78% | 42.81% |
Intangible Assets out of Total Assets |
0.51 | 0.57 | 0.00 |
Share Based Compensation of Revenue |
1.48% | 1.51% | 1.54% |
Graham Net Nets |
0.11 | 0.05 | 0.05 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(3.27%) | (3.27%) | (3.27%) |
Free Cash Flow Yield |
(14.14%) | (9.43%) | (9.43%) |
Revenue per Share |
12.09 | 10.74 | 9.77 |
Operating CF per Share |
(0.77) | 0.55 | 0.16 |
Capex per Share |
(0.87) | (0.76) | (0.59) |
Free Cash Flow per Share |
(1.64) | (0.21) | (0.42) |
Cash per Share |
1.16 | 0.04 | 0.00 |
Shareholders Equity per Share |
14.07 | 13.17 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
14.07 | 13.17 | 0.00 |
Free Cash Flow |
(420.00) | (53.00) | (107.00) |
Working Capital |
646.00 | 229.00 | — |
Capital Expenditures |
(223.00) | (193.00) | (148.00) |
Net Current Asset Value |
329.00 | 68.00 | 0.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.07 | 0.07 | 0.06 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.22 | 0.20 | 0.00 |
Cash ROIC |
(10.74%) | (1.59%) | 0.00% |
Accounts Receivable Turnover |
8.06 | 0.00 | 0.00 |
Accounts Payable Turnover |
7.73 | 0.00 | 0.00 |
Inventory Turnover |
4.36 | 0.00 | 0.00 |
Average Days of Payables |
41.84 | 63.04 | 0.00 |
Days of Inventory on Hand |
87.53 | 95.63 | 0.00 |
Average Receivables |
385.00 | — | — |
Average Payables |
184.00 | — | — |
Average Inventory |
326.00 | — | — |
Average Assets |
4,415.50 | 2,100.50 | — |
Average Common Equity |
3,471.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026